TRAIL Sensitization of PC3 Prostate Cancer Cells by Doxorubicin Can Be Blocked by the Antioxidant N-Acetyl-Cysteine or by the Iron Chelator Deferoxamine
October 2006
in “
Clinical Cancer Research
”
Studysummary This study found that doxorubicin-induced oxidative stress downregulates FLIPs and phosphorylates EF2, sensitizing prostate cancer cells to TRAIL; antioxidants may reduce doxorubicin's effectiveness, warranting further investigation.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on clincancerres.aacrjournals.org →